Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH) - PubMed
10 hours ago
- #Non-Communicable Diseases
- #Obesity Epidemiology
- #Metabolic Liver Disease
- Obesity and excess adiposity are increasingly prevalent globally, triggering a state of metabo-inflammation that leads to systemic insulin resistance and pro-inflammatory and fibrogenic states.
- Metabolically driven cell stress, injury, and death due to metabolic disruptions activate innate immune signals, promoting fibrogenesis and organ dysfunction in end-organ diseases.
- Key non-communicable diseases associated with obesity and metabo-inflammation include atherosclerotic vascular disease, hypertension, type 2 diabetes mellitus, chronic kidney disease, heart failure with preserved ejection fraction, and metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH).
- MASLD/MASH is part of a cluster of non-communicable diseases that account for the majority of premature deaths worldwide, with rates projected to rise due to obesity, diabetes, and metabolic syndromes.
- The manuscript reviews the epidemiology, biological relationships between obesity and MASLD, mechanistic links between MASLD and other non-communicable diseases, and clinical impacts on patients.
- A holistic approach to caring for individuals with MASLD is recommended, focusing on treating obesity as a root cause while monitoring liver status for potential liver-targeted therapeutics.
- Best practices for obesity-oriented treatment of MASLD are discussed, including the rationale for addressing obesity to manage liver disease.